Eli Lilly Stock

2024 - 2 - 6

Eli Lilly Stocks Soar on Strong Q4 Performance and Weight-Loss Drug Success

diabetes treatments - Eli Lilly - pharmaceutical industry - weight-loss drugs

Eli Lilly's stock leaps to record highs with impressive financial results and booming demand for weight-loss drugs.

Eli Lilly achieved remarkable success in the fourth quarter with soaring stock prices and exceeded market expectations in sales. The company's robust financial performance was driven by the launch of the new weight loss drug, Zepbound, which received FDA approval in November. The quarter also saw a significant increase in U.S. drug prices, particularly driven by the diabetes treatment Mounjaro. Despite the rise in domestic prices, international drug prices decreased, balancing out the overall market positioning of Eli Lilly.

The success of Eli Lilly's growth products, including Verzenio and Jardiance, contributed to a 9% revenue growth in Q4 2023, reaching $5.27 billion. The company's positive outlook for 2024 reflects strong profit forecasts, primarily fueled by the escalating demand for the recently-approved weight-loss drug. Investors witnessed a shift in market value, with Eli Lilly gaining $140 billion while Tesla lost $210 billion, showcasing the dynamic nature of the pharmaceutical and technology sectors.

Eli Lilly's stock surge can be attributed to the promising future of its obesity and diabetes medications, indicating substantial growth potential. Analysts and experts anticipate further market advancements for Eli Lilly, particularly in the realm of weight-loss drugs and diabetes treatments, reinforcing the company's position as a key player in the pharmaceutical industry.

The rise of Eli Lilly's stock to record levels signals a turning point for the company, propelled by the success of Zepbound and other key products. As Eli Lilly continues to outperform expectations and expand its market presence, the focus remains on innovative drug developments and strategic growth initiatives.

Eli Lilly's significant market impact and financial success position the company as a frontrunner in the pharmaceutical landscape, with a strong emphasis on meeting the rising demand for effective weight-loss and diabetes treatments. The progressive outlook for Eli Lilly underscores its commitment to advancing healthcare solutions and driving sustainable growth in the industry.

Post cover
Image courtesy of "Investor's Business Daily"

Eli Lilly Stock Veers Higher On Fourth-Quarter Beat (Investor's Business Daily)

Eli Lilly Scored a strong Q4 win and provided healthy guidance Tuesday. Shares moved toward a profit-taking zone following a January breakout.

Post cover
Image courtesy of "MarketWatch"

Eli Lilly's stock leaps toward a record as a 16% jump in prices ... (MarketWatch)

U.S. prices for Lilly's drugs climbed 27%, driven by diabetes treatment Mounjaro, while prices outside the U.S. fell.

Post cover
Image courtesy of "CNBC"

Eli Lilly results blow past estimates on strong Zepbound launch ... (CNBC)

The quarterly results are the first to include sales of Eli Lilly's new weight loss drug Zepbound, which won FDA approval in early November.

Post cover
Image courtesy of "Investors | Eli Lilly and Company"

Lilly Reports Strong Fourth-Quarter 2023 Financial Results and ... (Investors | Eli Lilly and Company)

Growth Products(ii) revenue increased 9% to $5.27 billion in Q4 2023, led by Verzenio and Jardiance. Pipeline progress included FDA approval of Zepbound for ...

Post cover
Image courtesy of "Financial Times"

Live news: US aviation regulator to put 'more boots on the ground' at ... (Financial Times)

US stocks opened higher on Tuesday as investors looked ahead to fresh commentary from Federal Reserve officials and a flurry of fourth-quarter corporate results ...

Post cover
Image courtesy of "Reuters"

Lilly expects strong 2024 profit on rising weight-loss drug demand (Reuters)

Eli Lilly on Tuesday forecast 2024 profit above Wall Street estimates on soaring demand for its recently approved weight-loss drug, and said the treatment ...

Post cover
Image courtesy of "Forbes"

Tesla Now Worth $110 Billion Less Than Weight Loss Drug Maker ... (Forbes)

Tesla has lost $210 billion of market value in 2024 while Eli Lilly gained $140 billion, as investors trade ditch their EV optimism for the GLP-1 craze.

Post cover
Image courtesy of "The Seattle Times"

Weight loss, diabetes drugs propel Eli Lilly to largely better-than ... (The Seattle Times)

The popular diabetes treatment Mounjaro pushed Eli Lilly past fourth-quarter forecasts, and the drugmaker expects 2024 to turn out largely better than ...

Post cover
Image courtesy of "ABC News"

Weight loss, diabetes drugs propel Eli Lilly to better-than-expected ... (ABC News)

The popular diabetes treatment Mounjaro pushed Eli Lilly past fourth-quarter forecasts, and the drugmaker expects 2024 to turn out largely better than ...

Post cover
Image courtesy of "Barron's"

Eli Lilly Stock Rises. Earnings Were Boosted by Obesity Drug Sales. (Barron's)

shares jumped again on Tuesday, as signs continue to point to the drug maker's new obesity and diabetes medicines growing into earthshaking blockbusters. Lilly ...

Post cover
Image courtesy of "Motley Fool"

Why Eli Lilly Stock Jumped as Much as 5.1% Today Then Gave Up ... (Motley Fool)

The midpoint of the company's full-year 2024 revenue guidance range also topped the average analysts' estimate. Lilly should have tremendous growth prospects ...

Post cover
Image courtesy of "Yahoo Finance"

Why Eli Lilly Stock Jumped as Much as 5.1% Today Then Gave Up ... (Yahoo Finance)

The company reported Q4 revenue of $9.35 billion, up 28% year over year. This result came in well above the average analysts' revenue estimate of $8.93 billion.

Post cover
Image courtesy of "Markets Insider"

Eli Lilly rides the weight-loss-drug wave to record, hits $700 billion (Markets Insider)

"We haven't scratched the surface in terms of how big the [GLP-1 weight loss] drugs are going to get," Mizuho strategist Jared Holz said.

Eli Lilly's stock leaps toward a record as a 16% jump in prices ... (Morningstar.com)

Shares of Eli Lilly and Co. rallied toward yet another record close on Tuesday, after the drug maker's fourth-quarter profit beat expectations, helped by a 16% ...

Post cover
Image courtesy of "tastytrade"

Eli Lilly Set for New Highs as Zepbound Sales Surge (tastytrade)

The drugmaker had better results than expected in Q4 earnings, and their new drug Zepbound shows great results in trial.

Eli Lilly & Co. stock underperforms Tuesday when compared to ... (MarketWatch)

Shares of Eli Lilly & Co. slipped 0.17% to $705.03 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P.

Why Eli Lilly Stock Jumped as Much as 5.1% Today Then Gave Up ... (Nasdaq)

Shares of Eli Lilly (NYSE: LLY) jumped as much as 5.1% on Tuesday. However, as of 11:37 a.m. ET, the big pharma stock was down by 0.5%.

Eli Lilly Earns IBD Stock Rating Upgrade (Investor's Business Daily)

On Wednesday, Eli Lilly (LLY) got an upgrade for its IBD SmartSelect Composite Rating from 90 to 96. The new score means the company is now outperforming ...

Post cover
Image courtesy of "STAT"

The GLP-1 panic is alive and well (STAT)

Today's biotech newsletter includes the arrival of Scion Life Sciences, GLP-1 panic, and the weight of expectations on Eli Lilly.

Post cover
Image courtesy of "The Wall Street Journal"

Why Eli Lilly Deserves to Unseat Tesla Among the Magnificent Seven (The Wall Street Journal)

Pharma company's market cap has surpassed Tesla's, thanks to rapid growth of its GLP-1 business.

Post cover
Image courtesy of "CNBC"

Jim Cramer says recent moves in Apple, Chipotle and Eli Lilly ... (CNBC)

"When you see some action that doesn't make sense, keep in mind that authentic stupidity is a perfectly plausible explanation," CNBC's Jim Cramer said.

Post cover
Image courtesy of "Benzinga"

Apple, Chipotle And Eli Lilly Stocks Baffle Jim Cramer With Unusual ... (Benzinga)

Cramer questioned the rationale behind the market's behavior, emphasizing that not all stock movements are logical, especially during earnings season.

Post cover
Image courtesy of "Yahoo Finance"

Eli Lilly CFO: Weight-loss drug demand will outstrip GLP-1 supply ... (Yahoo Finance)

Eli Lilly blew past Wall Street estimates for its latest earnings but faces pressure ahead to deliver strong results for the year.

Post cover
Image courtesy of "Nasdaq"

Novo Nordisk vs. Eli Lilly: Which Mega-Cap Healthcare Stock is a ... (Nasdaq)

Healthcare stocks LLY and NVO have crushed broader market returns in the past two decades. But with competition heating up over obesity drugs, ...

Post cover
Image courtesy of "TheStreet"

Analysts revamp Eli Lilly stock price target on weight-loss drugs (TheStreet)

Ten years ago, the CDC said, no state had an adult obesity prevalence at or above 35%. “Our updated maps send a clear message that additional support for ...

Post cover
Image courtesy of "Prescott Daily Courier"

Analysts revamp Eli Lilly stock price target on weight-loss drugs (Prescott Daily Courier)

In November, Eli Lilly (LLY) won approval from the U.S. Food & Drug Administration for its obesity treatment Zepbound [terzepatide]. Zepbound played an ...

Explore the last week